1. Production and evaluation of three kinds of vaccines against largemouth bass virus, and DNA vaccines show great application prospects.
- Author
-
Hu T, Wang Y, Wang Y, Cui H, Zhang J, Chen H, Wu B, Hao S, Chu CC, Wu Y, and Zeng W
- Subjects
- Animals, Vaccines, Inactivated immunology, Vaccines, Inactivated administration & dosage, Immunity, Humoral, Ranavirus immunology, Vaccines, Subunit immunology, Vaccines, Subunit administration & dosage, Immunity, Cellular, Vaccines, DNA immunology, Vaccines, DNA administration & dosage, Fish Diseases prevention & control, Fish Diseases immunology, Bass immunology, Viral Vaccines immunology, Viral Vaccines administration & dosage, DNA Virus Infections veterinary, DNA Virus Infections prevention & control, DNA Virus Infections immunology
- Abstract
Largemouth bass virus (LMBV) infections has resulted in high mortality and economic losses to the global largemouth bass industry and has seriously restricted the healthy development of the bass aquaculture industry. There are currently no antiviral therapies available for the control of this disease. In this study, we developed three types of vaccine against LMBV; whole virus inactivated vaccine (I), a subunit vaccine composed of the major viral capsid protein MCP (S) as well as an MCP DNA vaccine(D), These were employed using differing immunization and booster strategies spaced 2 weeks apart as follows: II, SS, DD and DS. We found that all vaccine groups induced humoral and cellular immune responses and protected largemouth bass from a lethal LMBV challenge to varying degrees and DD produced the best overall effect. Specifically, the levels of specific IgM in serum in all immunized groups were elevated and significantly higher than those in the control group. Moreover, the expression of humoral immunity (CD4 and IgM) and cellular immunity (MHCI-α) as well as cytokines (IL-1β) was increased, and the activity of immunity-related enzymes ACP, AKP, LZM, and T-SOD in the serum was significantly enhanced. In addition, the relative percent survival of fish following an LMBV lethal challenge 4 weeks after the initial immunizations were high for each group: DD(89.5 %),DS(63.2 %),SS(50 %) and II (44.7 %). These results indicated that the MCP DNA vaccine is the most suitable and promising vaccine candidate for the effective control of LMBV disease., Competing Interests: Declaration of competing interest We declare that we have no financial and personal relationships with other people or organizations that can inappropriately influence our work, there is no professional or other personal interest of any nature or kind in any product, service and/or company that could be construed as influencing the position presented in the manuscript., (Copyright © 2024 Elsevier Ltd. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF